Business Description
Cellivery Therapeutics Inc
ISIN : KR7268600004
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -0.88 | |||||
Debt-to-Equity | -1.83 | |||||
Debt-to-EBITDA | -2.29 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -14.53 | |||||
Beneish M-Score | -3.79 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 179.3 | |||||
3-Year EBITDA Growth Rate | -9.2 | |||||
3-Year EPS without NRI Growth Rate | -40 | |||||
3-Year FCF Growth Rate | 23.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.04 | |||||
Days Inventory | 31.83 | |||||
Days Sales Outstanding | 26.66 | |||||
Days Payable | 17.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | 5.98 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -0.91 | |||||
Operating Margin % | -66.88 | |||||
Net Margin % | -38.48 | |||||
FCF Margin % | -2.6 | |||||
ROA % | -27.91 | |||||
ROIC % | -22.97 | |||||
3-Year ROIIC % | -3.97 | |||||
ROC (Joel Greenblatt) % | -137.71 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.86 | |||||
EV-to-EBIT | -15.81 | |||||
EV-to-EBITDA | -18.41 | |||||
EV-to-Revenue | 13.03 | |||||
EV-to-FCF | -501.8 | |||||
Earnings Yield (Greenblatt) % | -6.33 | |||||
FCF Yield % | -0.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cellivery Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 22,685.393 | ||
EPS (TTM) (â‚©) | -235 | ||
Beta | 0.96 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (â‚©) | 0 | ||
20-Day SMA (â‚©) | 6680 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (â‚©) | 6680 - 6680 | ||
Shares Outstanding (Mil) | 37.14 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cellivery Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cellivery Therapeutics Inc Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Cellivery Therapeutics Inc Frequently Asked Questions
What is Cellivery Therapeutics Inc(XKRX:268600)'s stock price today?
When is next earnings date of Cellivery Therapeutics Inc(XKRX:268600)?
Does Cellivery Therapeutics Inc(XKRX:268600) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |